← All trials
NCT05188729
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Sep 29, 2023
- Completion date
- Sep 29, 2023
- First posted
- Jan 12, 2022
- Last posted
- Sep 15, 2022
- Enrollment
- 66
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Verrica Pharmaceuticals Inc.Lead sponsor
- HeartcoR SolutionsCollaborator
- Veristat, Inc.Collaborator
- Q2 solutionsCollaborator
- MyonexCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.